PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics announced the appointments of Scott Applebaum as its President and Richard Morris as its EVP and CFO.

SAN DIEGO, November 15, 2017 – ChemDiv Inc., a fully integrated California-based CRO, announced that it has entered into a three-way co-development agreement with Context Therapeutics and Torrey Pines Investment to advance research and development in the area of Sigma1 dysfunction associated with early onset neurodegenerative diseases.

PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis, and neurodegenerative disease, today announced that the company has entered into agreements with three research partners.